Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.

47 – 49 Interestingly, BRCA1 carriers appear to develop OC at an average of ~7 years earlier versus nonhereditary OC patients, while BRCA2 carriers do not display a strong trend for earlier diagnosis ( Table 1 ). 47 , 50 – 53 BRCA1 mutations account for over 80% of BRCA -associated OC diagnosed below the age of 50, while BRCA2 carriers account for ~60% of BRCA -associated OC diagnosed at >60 years old, despite the higher prevalence of BRCA1 versus BRCA2 mutations in OC.

also in 5,725 other papers